GERMANTOWN, Md., May 15, 2018 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, provides a business update and reported its financial results for the first quarter ended March 31, 2018 .
We remain committed to the development of NSI-566, our lead stem cell therapy candidate, and were pleased to complete the first surgery in the second cohort of our ongoing Phase 1 clinical trial in patients with chronic spinal cord injury, said Rich Daly, President & Chief Executive Officer. We anticipate initiating a clinical trial for NSI-566 in chronic stroke in China and have targeted mid-2018 to begin dosing. We continue …
Read the full article at: https://globenewswire.com/news-release/2018/05/15/1502397/0/en/Neuralstem-Provides-Business-Update-and-Reports-First-Quarter-2018-Fiscal-Results.html